Navigation Links
NIH media availability: Protein linked to increased risk of heart failure and death in older adults
Date:8/29/2012

WHAT: A protein known as galectin-3 can identify people at higher risk of heart failure, according to new research supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. This research is based on work from the NHLBI's Framingham Heart Study, which began in 1948 and has been the leading source of research findings about heart disease risk factors.

"Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community," will be published online August 29 in the Journal of the American College of Cardiology and in the October 2 print issue.

Heart failure occurs when the heart cannot fill with enough blood and/or pump enough blood to meet the body's needs. Galactin-3 has recently been associated with cardiac fibrosis, a condition in which scar tissue replaces heart muscle, and cardiac fibrosis plays an important role in the development of heart failure.

Heart failure carries enormous risk for death or a lifetime of disability and often there are few warning signs of impending heart failure. Measuring levels of galectin-3 in the blood may offer a way to identify high-risk individuals who could benefit from treatments to prevent debilitating heart failure and death. Early identification of predisposed individuals would allow treatment to begin long before heart failure develops and could help people at high risk for heart failure to live longer, more active lives.

Galectin-3 levels were measured in 1996-1998 as part of a routine examination of 3,353 participants enrolled in the Offspring Cohort of the Framingham Heart Study. At the time of measurement the average age of the participants was 59 years old. During an average follow-up of 11 years, 166 participants (5.1 percent) had a first heart failure event. Among the 25 percent of people with the highest galectin-3 levels (ranging from 15.4 to 52.1 nanograms per milliliter) the annual rate of heart failure was 12 per 1,000 people compared with 3 per 1,000 people for the 25 percent of participants with the lowest galectin-3 levels (ranging from 3.9 to 12 nanograms per milliliter). Fifty-three percent of participants were women.

Spironolactone and other related drugs believed to counteract cardiac fibrosis have been shown to improve outcomes in heart failure patients. Future research will be needed to determine whether treatment with these or other drugs can benefit healthy patients with elevated galectin-3 levels.


'/>"/>
Contact: NHLBI Communications Office
NHLBI_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related biology technology :

1. ASAE, TMG Custom Media Collaborate to Launch New Print-Plus-Digital Strategy for Associations Now Magazine
2. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
3. Mold Threats Debby Flood Victims, Molderizer Reaches Out With Non-Toxic Mold Remediation Products
4. Air Innovations’ Environmental Control Projects Featured in Trade Media
5. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
6. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
7. The Scientist Magazine’s 2012 Multimedia Awards—Call for Entries
8. Big Saver: Molderizer Offers 30% Mold Remediation Products Price Cut
9. Nanoscale magnetic media diagnostics by rippling spin waves
10. Protein that helps tumor blood vessels mature could make cancer drugs more effective
11. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Today, ... professionals, has announced the addition of 5 new courses to its prospectus. These ... with Regulation 21 CFR Part 11 on Electronic Records and Electronic Signatures (Part ...
(Date:9/20/2017)... CT (PRWEB) , ... September 20, 2017 , ... ... announced today that it has appointed Vishwas Paralkar to the role of chief ... tumor targeting technology. He will report to Cybrexa’s president and CEO, Per Hellsund. ...
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports ... after standard medicine failed. Many of these people had lost all hope. ... Free Download (pdf) , “Neil takes readers on a riveting ...
(Date:9/19/2017)... ... September 19, 2017 , ... A ... funded early-stage tech companies. “Grit” author Angela Duckworth and her team at Character ... community is Cooley, an international law firm with decades of experience supporting high-growth ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):